ARS Pharmaceuticals (SPRY) Equity Ratio (2020 - 2026)

ARS Pharmaceuticals has disclosed Equity Ratio across 7 years of filings, most recently posting 0.21 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.21, down 69.52% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.21 (down 69.52% YoY), and the FY2025 annual result was 0.35, down 52.32% from the prior year.
• Equity Ratio came in at 0.21 for Q1 2026 at ARS Pharmaceuticals, down from 0.35 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.99 in Q4 2023 to a low of 0.19 in Q3 2022.
• The 5-year median for Equity Ratio is 0.73 (2024), against an average of 0.6.
• Across the five-year window, Equity Ratio slumped 119.64% in 2022 and surged 886.58% in 2023, its largest moves.
• ARS Pharmaceuticals' Equity Ratio stood at 0.97 in 2022, then climbed by 2.06% to 0.99 in 2023, then slipped by 26.1% to 0.73 in 2024, then sank by 52.32% to 0.35 in 2025, then sank by 38.86% to 0.21 in 2026.
• The last three Equity Ratio figures came in at 0.21 (Q1 2026), 0.35 (Q4 2025), and 0.4 (Q3 2025), per Business Quant data.